Orexo´s partner Gesynta Pharma announces positive results from phase 1 study for OX-MPI

Uppsala, Sweden – May 15, 2020 – Orexo´s partner, Gesynta Pharma,  today announces positive phase I results for OX-MPI (GS-248). Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), aims to develop a treatment for the microvascular diseases in chronic inflammatory conditions. The purpose of the first clinical study was to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties of OX-MPI (GS-248) after single and multiple ascending doses to healthy subjects.

The results support further clinical development of OX-MPI (GS-248) and a clinical phase II study is being planned.

The study will be presented at the 2020 EULAR e-congress June 3-6.

For more information read Gesynta Pharma´s press release attached below.

About Us

Develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercialize its lead product Zubsolv® for treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 844,8 million and the number of employees was 127. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.